This company listing is no longer active
MorphoSys Valuation
Is MOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MOR?
Other financial metrics that can be useful for relative valuation.
What is MOR's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €2.53b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 17.1x |
Enterprise Value/EBITDA | -9.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MOR's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 11.7x | ||
BSLN Basilea Pharmaceutica | 3.6x | 9.2% | CHF 543.6m |
KURN Kuros Biosciences | 17.3x | n/a | CHF 908.3m |
IDIA Idorsia | 1.7x | 39.9% | CHF 214.0m |
MOLN Molecular Partners | 24.2x | 53.2% | CHF 190.5m |
MOR MorphoSys | 10.5x | 25.0% | CHF 2.5b |
Price-To-Sales vs Peers: MOR is good value based on its Price-To-Sales Ratio (10.5x) compared to the peer average (11.1x).
Price to Earnings Ratio vs Industry
How does MOR's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the European Biotechs industry average (9.5x).
Price to Sales Ratio vs Fair Ratio
What is MOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 10.5x |
Fair PS Ratio | 7.5x |
Price-To-Sales vs Fair Ratio: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the estimated Fair Price-To-Sales Ratio (7.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 102.00 | CHF 59.21 -42.0% | 16.5% | CHF 63.57 | CHF 37.39 | n/a | 6 |
Oct ’25 | n/a | CHF 59.21 0% | 16.5% | CHF 63.57 | CHF 37.39 | n/a | 6 |
Sep ’25 | n/a | CHF 59.21 0% | 16.5% | CHF 63.57 | CHF 37.39 | n/a | 6 |
Aug ’25 | CHF 102.00 | CHF 55.35 -45.7% | 25.3% | CHF 64.11 | CHF 29.22 | n/a | 7 |
Jul ’25 | CHF 102.00 | CHF 57.61 -43.5% | 25.3% | CHF 66.73 | CHF 30.42 | n/a | 7 |
Jun ’25 | CHF 102.00 | CHF 57.61 -43.5% | 25.3% | CHF 66.73 | CHF 30.42 | n/a | 7 |
May ’25 | CHF 102.00 | CHF 57.61 -43.5% | 25.3% | CHF 66.73 | CHF 30.42 | n/a | 7 |
Apr ’25 | CHF 102.00 | CHF 56.48 -44.6% | 25.3% | CHF 65.42 | CHF 29.82 | n/a | 7 |
Mar ’25 | CHF 102.00 | CHF 47.43 -53.5% | 36.4% | CHF 64.03 | CHF 20.71 | n/a | 8 |
Feb ’25 | CHF 102.00 | CHF 29.29 -71.3% | 33.5% | CHF 43.91 | CHF 14.01 | n/a | 10 |
Jan ’25 | CHF 102.00 | CHF 29.21 -71.4% | 33.6% | CHF 44.28 | CHF 14.13 | n/a | 10 |
Dec ’24 | CHF 102.00 | CHF 30.03 -70.6% | 33.3% | CHF 45.34 | CHF 14.47 | n/a | 8 |
Nov ’24 | CHF 102.00 | CHF 33.05 -67.6% | 17.8% | CHF 43.32 | CHF 24.07 | n/a | 9 |
Oct ’24 | CHF 102.00 | CHF 30.14 -70.5% | 29.1% | CHF 42.90 | CHF 12.87 | n/a | 9 |
Sep ’24 | CHF 102.00 | CHF 26.81 -73.7% | 38.9% | CHF 43.18 | CHF 11.99 | n/a | 8 |
Aug ’24 | CHF 102.00 | CHF 26.89 -73.6% | 40.0% | CHF 44.84 | CHF 11.93 | CHF 102.00 | 8 |
Jul ’24 | CHF 102.00 | CHF 25.02 -75.5% | 50.9% | CHF 46.00 | CHF 12.23 | CHF 102.00 | 8 |
Jun ’24 | CHF 102.00 | CHF 22.45 -78.0% | 59.3% | CHF 45.75 | CHF 11.68 | CHF 102.00 | 8 |
May ’24 | CHF 102.00 | CHF 17.99 -82.4% | 58.8% | CHF 41.25 | CHF 10.80 | CHF 102.00 | 8 |
Apr ’24 | CHF 102.00 | CHF 18.09 -82.3% | 58.8% | CHF 41.49 | CHF 10.87 | CHF 102.00 | 8 |
Mar ’24 | CHF 102.00 | CHF 18.02 -82.3% | 59.2% | CHF 41.48 | CHF 10.86 | CHF 102.00 | 8 |
Feb ’24 | CHF 102.00 | CHF 23.15 -77.3% | 76.2% | CHF 64.18 | CHF 10.86 | CHF 102.00 | 9 |
Jan ’24 | CHF 102.00 | CHF 24.72 -75.8% | 67.8% | CHF 64.14 | CHF 11.84 | CHF 102.00 | 9 |
Dec ’23 | CHF 102.00 | CHF 28.58 -72.0% | 60.9% | CHF 63.82 | CHF 12.76 | CHF 102.00 | 9 |
Nov ’23 | CHF 102.00 | CHF 35.05 -65.6% | 39.6% | CHF 63.98 | CHF 17.72 | CHF 102.00 | 9 |
Oct ’23 | CHF 102.00 | CHF 35.94 -64.8% | 34.1% | CHF 62.85 | CHF 23.20 | CHF 102.00 | 9 |
Analyst Forecast: Target price is lower than the current share price.